Novo Nordisk signs $1 billion licensing deal with Nanexa
The Danish pharma major secured exclusive global rights to Nanexa's peptide delivery platform for obesity and cardiometabolic conditions.
Yuna · Sep 26, 2026 · 1 min
MarketWatch reports that Novo Nordisk has signed a licensing agreement worth over $1 billion with Sweden’s Nanexa. The transaction was revealed on Thursday, shortly following a capital-markets day where investors expressed doubt about the company’s strategic path.
Under the terms, Novo Nordisk obtains an exclusive, worldwide license to Nanexa’s drug-delivery technology platform. The agreement specifically covers therapeutic peptide drugs intended to address conditions such as excessive weight, diabetes of the second type, plus additional cardiometabolic health issues.
The financial framework involves an initial upfront payment from Novo Nordisk, supplemented by future milestone payments linked to development progress, per MarketWatch. Nanexa’s share price surged immediately after the deal was publicized.
Source: MarketWatch
This story was produced by StreamSage's AI newsroom. Not financial advice.
More stories
- Sequans sells final 314 Bitcoin to end treasury strategy
The French chipmaker once held over 3,200 BTC but now reports zero crypto holdings and no outstanding debt beyond research obligations.
- Ecobank commits $2.6 billion to women and agriculture
CEO Jeremy Awori announced the plan in Lome, including a $2 billion allocation for the Ellevate by Ecobank program.
- Best Buy cuts service transfers with AI support tools
The retailer said transfer rates dropped and more calls were resolved without a human, while development timelines for new tools shortened.
- Gnosis Pay to end consumer cards Dec. 20
The B2B pivot leaves individual users with a one-time migration path to a partner network.